Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/1/2018 |
| Start Date: | December 2009 |
| End Date: | January 2035 |
A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma
The purpose of this study is to see what effects, good and/or bad, proton based radiation
combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.
combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.
Inclusion Criteria:
* Adenocarcinoma of the prostate.
Exclusion Criteria:
- Previous prostate cancer treatment such as chemotherapy and/or pelvic radiation.
- Active inflammatory bowel disease (diverticulitis, Crohn's disease or ulcerative
colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not
affecting the rectum are allowed.)
- History of hip replacement.
- Prior intrapelvic surgery. This includes the following:
- Transrectal or rectal surgery other than polypectomy or hemorrhoid removal or banding
- Transabdominal pelvic surgery
- Bladder surgery
- Prior myocardial infarction (MI) or congestive heart failure (CHF).
- Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use
during radiation.
We found this trial at
1
site
2015 Jefferson St
Jacksonville, Florida 32206
Jacksonville, Florida 32206
(904) 588-1800
University of Florida Proton Therapy Institute When the University of Florida Proton Therapy Institute opened...
Click here to add this to my saved trials
